근시성 맥락막 신생혈관에 대한 유리체강내 베바시주맙 주입술 장기간 치료효과

Long-term Therapeutic Effect of Intravitreal Bevacizumab (Avastin) on Myopic Choroidal Neovascularization

Purpose: To evaluate the long-term therapeutic effects of intravitreal bevacizumab on myopic choroidal neovascularization (CNV). Methods: Medical records of 6 patients who underwent intravitreal bevacizumab injection for myopic CNV and were followed for more than 2 years, were retrospectively investigated. The best corrected visual acuity was compared at 1,3,12, and 24 months after injection. Two years after the injection, a fluorescein angiography and optical coherence tomography (OCT) were performed to evaluate the central macular thickness and leakage of CNV. Results: The mean best corrected visual acuity was 1.16 ± 0.43 (logMAR), 0.45 ± 0.21 (logMAR), 0.29 ± 0.23 (logMAR), 0.14 ± 0.11 (logMAR), and 0.11 ± 0.06 (logMAR) at baseline, 1, 3, 12, and 24 months after injection, respectively. The average number of injections was 1.33. In OCT, 2 years after bevacizumab injection, central foveal thickness was significantly decreased as compared to the baseline, and fluorescein angiography showed no leakage of fluorescein. Conclusions: Intravitreal bevacizumab injection for the treatment of myopic CNV was effective in maintaining postoperative visual acuity for 2 years. J Korean Ophthalmol Soc 2011;52(1):34-40